Top

Gepubliceerd in:

01-05-2015

Schildkliercarcinoom

Auteur: Dr. Romana T. Netea-Maier

Gepubliceerd in: Bijblijven | Uitgave 4/2015

Samenvatting

Schildkliercarcinomen zijn zeldzame maligne tumoren. Slechts 5 % van de palpabele schildkliernoduli waarmee een patiënt zich bij de huisarts presenteert is maligne. Cytologische schildklierpunctie en echografie van de hals zijn de belangrijkste diagnostische onderzoeken voor patiënten met een schildkliernodus. De conventionele behandeling van patiënten met schildkliercarcinomen bestaat uit een totale thyroïdectomie eventueel gevolgd door een behandeling met radioactief jodium. De prognose van patiënten met schildkliercarcinomen is afhankelijk van het histologische type en de uitgebreidheid van de ziekte. De meerderheid van de patiënten geneest echter van de ziekte. In deze bijdrage wordt een overzicht gegeven van de diagnostiek en de behandeling van verschillende vormen van schildkliercarcinoom specifiek gericht op de Nederlandse praktijk.

vorige artikel Bijzondere endocrinologie, epidemiologie en huisartsenperspectief

volgende artikel Schildklier en zwangerschap

Russ G, Leboulleux S, Leenhardt L, Hegedus L. Thyroid incidentalomas: epidemiology, risk stratification with ultrasound and workup. Eur Thyroid J. 2014;3:154–63.PubMedCentralPubMedCrossRef

Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch Intern Med. 1994;154:1838–40.PubMedCrossRef

Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–7.PubMedCrossRef

Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115:3801–7.PubMedCrossRef

Reynolds RM, Weir J, Stockton DL, Brewster DH, Sandeep TC, Strachan MW. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol (Oxf). 2005;62:156–62.CrossRef

Netea-Maier RT, Aben KK, Casparie MK, et al. Trends in incidence and mortality of thyroid carcinoma in The Netherlands between 1989 and 2003: correlation with thyroid fine-needle aspiration cytology and thyroid surgery. Int J Cancer. 2008;123:1681–4.PubMedCrossRef

Tucker MA, Jones PH, Boice JD Jr, et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The late effects study group. Cancer Res. 1991;51:2885–8.PubMed

Links TP, Huysmans DA, Smit JW, et al. [Guideline ‘Differentiated thyroid carcinoma’, including diagnosis of thyroid nodules]. Ned Tijdschr Geneeskd. 2007;151:1777–82.PubMed

Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.PubMedCrossRef

10.

Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915–42.PubMedCrossRef

11.

Leenhardt L, Erdogan MF, Hegedus L, et al. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J. 2013;2:147–59.PubMedCentralPubMedCrossRef

12.

Vriens D, Wilt JH de, Wilt GJ van der, Netea-Maier RT, Oyen WJ, Geus-Oei LF de. The role of [18F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature. Cancer. 2011;117:4582–94.PubMedCrossRef

13.

Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med. 1993;118:282–9.PubMedCrossRef

14.

Ravetto C, Colombo L, Dottorini ME. Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: a retrospective study in 37,895 patients. Cancer. 2000;90:357–63.PubMedCrossRef

15.

Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol. 2009;132:658–65.PubMedCrossRef

16.

Crippa S, Mazzucchelli L, Cibas ES, Ali SZ. The Bethesda System for reporting thyroid fine-needle aspiration specimens. Am J Clin Pathol. 2010;134:343–4; author reply 5.PubMedCrossRef

17.

Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367:705–15.PubMedCrossRef

18.

Alexander EK, Schorr M, Klopper J, et al. Multicenter clinical experience with the Afirma gene expression classifier. J Clin Endocrinol Metab. 2014;99:119–25.PubMedCrossRef

19.

Lee L, Mitmaker EJ, How J. The value of molecular diagnostics for indeterminate thyroid nodules. J Clin Endocrinol Metab. 2014;99:4062–5.PubMedCrossRef

20.

Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer. 2014;120:3627–34.PubMedCrossRef

21.

Brito JP, Hay ID, Morris JC. Low risk papillary thyroid cancer. BMJ. 2014;348:g3045.PubMedCrossRef

22.

Sevim T. Risk factors for permanent laryngeal nerve paralysis in patients with thyroid carcinoma. Clin Otolaryngol. 2007;32:378–83.PubMedCrossRef

23.

Dralle H, Sekulla C, Haerting J, et al. Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. Surgery. 2004;136:1310–22.PubMedCrossRef

24.

Rafferty MA, Goldstein DP, Rotstein L, et al. Completion thyroidectomy versus total thyroidectomy: is there a difference in complication rates? An analysis of 350 patients. J Am Coll Surg. 2007;205:602–7.PubMedCrossRef

25.

Flynn MB, Lyons KJ, Tarter JW, Ragsdale TL. Local complications after surgical resection for thyroid carcinoma. Am J Surg. 1994;168:404–7.PubMedCrossRef

26.

Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674–85.PubMedCrossRef

27.

Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663–73.PubMedCrossRef

28.

Klein Hesselink EN, Klein Hesselink MS, Bock GH de, et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol. 2013;31:4046–53.PubMedCrossRef

29.

Heemstra KA, Hamdy NA, Romijn JA, Smit JW. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid. 2006;16:583–91.PubMedCrossRef

30.

Roerink SH, Ridder M de, Prins J, et al. High level of distress in long-term survivors of thyroid carcinoma: results of rapid screening using the distress thermometer. Acta Oncol. 2013;52:128–37.PubMedCrossRef

Titel: Schildkliercarcinoom
Auteur: Dr. Romana T. Netea-Maier
Publicatiedatum: 01-05-2015
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Bijblijven / Uitgave 4/2015
Print ISSN: 0168-9428
Elektronisch ISSN: 1876-4916
DOI: https://doi.org/10.1007/s12414-015-0028-y

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 4/2015

Bijnierschorsinsufficiëntie

Schildklier en zwangerschap

Aandoeningen van de bijschildklier

Bijzondere endocrinologie, epidemiologie en huisartsenperspectief

Ziekte van Cushing

Neuro-endocriene tumoren